These results indicate that combining the c-MET inhibitor, Crizotinib, with either Poloppin or Poloppin-II arrests the growth of mutant KRAS-bearing cancer cells with greater efficacy than when the compounds are used independently, and suggest that c-MET inhibition acts synergistically with inhibition of the PLK PBD. Here, KRAS is linked to cancer.